The Drug Price Competition and Patent Term Restoration Act, also called the Hatch-Waxman act, seeks to balance the interests of brands and generics. The first generic applicant to get an abbreviated new drug application (ANDA) approved by the U.S. Food and Drug Administration (FDA) stands to gain a 180-day market exclusivity.
Responding to the rapid adoption of MaxVal’s products and services and growth of MaxVal’s customer base, a dedicated US-based Professional Services Organization (PSO) has been launched to streamline implementations and better serve clients. MaxVal is also pleased to announce that Murali Kalyanthaya has joined MaxVal to lead the new PSO team.
MaxVal announces updates to its symphony® product line to help organizations better manage their trademark workflow. In addition to these enhancements, MaxVal is also expanding its trademark service lines to include filings, prosecution, and renewals, leveraging its global partner network and Symphony platform to simplify and streamline common trademark processes.
The new version of Max-IDS™ harnesses the power of automation to provide a faster and simpler approach.
Visit us at IP Counsel Cafe “Parts Unknown: Global IP in an Increasingly Connected Yet Foreign World” in Palo Alto, California on May 7 and 8, 2019.
Aistemos’s patent intelligence software, Cipher, now includes MaxVal’s international patent litigation data
MaxVal announces that all of our software products and services now support the USPTO’s upcoming Private PAIR changes.
MaxVal’s E-Cigarettes report is now available through Patent LiveScape™, an analysis and reporting service that provides clients with interactive reports which extract actionable and predictive information. By leveraging data sciences best practices, MaxVal has constructed an interactive report that melds different yet related data sources into a comprehensive landscape, allowing the reader to dynamically explore relationships.
The USPTO recently announced its Relevant Prior Art (RPA) Initiative, seeking to leverage electronic resources to improve an examiner’s access to relevant information from applicant’s other related applications. These resources may include related U.S. applications, international applications under the PCT, and counterpart foreign applications by the same applicant.
Following the publication of our recent Technology Landscape study on CRISPR-Cas9, MaxVal announces the latest advanced publication on the genome editing system, CRISPR, which has become an extremely important tool in medical research. The demonstration of the reprogrammable nature of Cas9 served as a catalyst to widespread adoption of CRISPR systems in biomedical and agricultural research. The potential benefits of CRISPR gene editing in several challenging diseases such as Alzheimer’s, cancer, and numerous autoimmune diseases are being explored by researchers.